Home › PBT2 Recommended For Orphan Designation In Europe
 

Keywords :   


PBT2 Recommended For Orphan Designation In Europe

2015-04-29 03:49:41| drugdiscoveryonline Home Page

Prana Biotechnology is pleased to announce the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending designation of PBT2 for the treatment of Huntington disease as an orphan medicinal product to the European Commission (EC)

Tags: europe recommended designation orphan

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
09.05Skin Care Composition Prevents and Treats Pollution Damage
09.05Demand, crop prospects, global geopolitics: What's ahead?
09.05Scalstrm and EZDRM partner on video content security
09.05Appvion launches EarthChem sustainable direct thermal portfolio
09.05Glatfelter Reports Financial Results
09.05Maryland Adopts PaintCare Program
09.05Society of Cosmetic Chemists Intermountain West to Host Healthy Bite Oral Care Symposium
09.05A.Celli and Akinal Tekstil Collaborate on Line Installation
More »